This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 11
  • /
  • CHMP Positive for Prostate Cancer Treatment
News

CHMP Positive for Prostate Cancer Treatment

Read time: 1 mins
Published:13th Nov 2023
"

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Talzenna

The marketing authorisation holder for this medicinal product is Pfizer. The CHMP adopted a new indication for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adults for whom chemotherapy is not clinically indicated.

For information, the full indications for Talzenna will be as follows: Talzenna is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

Condition: Prostate Cancer
Type: drug
How do you prefer to access medical updates and information?

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.